CN116390926A - 四氢吡唑并-吡嗪基-二氢咪唑酮或四氢吡唑并-吡啶基-二氢咪唑酮化合物及其使用方法 - Google Patents
四氢吡唑并-吡嗪基-二氢咪唑酮或四氢吡唑并-吡啶基-二氢咪唑酮化合物及其使用方法 Download PDFInfo
- Publication number
- CN116390926A CN116390926A CN202180063652.8A CN202180063652A CN116390926A CN 116390926 A CN116390926 A CN 116390926A CN 202180063652 A CN202180063652 A CN 202180063652A CN 116390926 A CN116390926 A CN 116390926A
- Authority
- CN
- China
- Prior art keywords
- group
- alkyl
- compound
- alkoxy
- haloalkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Gastroenterology & Hepatology (AREA)
- Child & Adolescent Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2020102955 | 2020-07-20 | ||
| CNPCT/CN2020/102955 | 2020-07-20 | ||
| CN2021070120 | 2021-01-04 | ||
| CNPCT/CN2021/070120 | 2021-01-04 | ||
| PCT/CN2021/107216 WO2022017338A1 (en) | 2020-07-20 | 2021-07-20 | Tetrahydropyrazolo-pyrazinyl-dihydroimidazolone or tetrahydropyrazolo-pyridinyl-dihydroimidazolone compounds and methods of using same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN116390926A true CN116390926A (zh) | 2023-07-04 |
Family
ID=77167918
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202180063652.8A Pending CN116390926A (zh) | 2020-07-20 | 2021-07-20 | 四氢吡唑并-吡嗪基-二氢咪唑酮或四氢吡唑并-吡啶基-二氢咪唑酮化合物及其使用方法 |
Country Status (16)
| Country | Link |
|---|---|
| US (3) | US12037339B2 (https=) |
| EP (1) | EP4182020A1 (https=) |
| JP (3) | JP7569443B2 (https=) |
| KR (2) | KR102936860B1 (https=) |
| CN (1) | CN116390926A (https=) |
| AU (2) | AU2021311567B2 (https=) |
| BR (1) | BR112023000932A2 (https=) |
| CA (1) | CA3186217A1 (https=) |
| CL (1) | CL2023000196A1 (https=) |
| CO (1) | CO2023001407A2 (https=) |
| IL (1) | IL299704A (https=) |
| MX (1) | MX2023000943A (https=) |
| PE (1) | PE20230854A1 (https=) |
| PH (1) | PH12023550130A1 (https=) |
| UA (1) | UA130727C2 (https=) |
| WO (1) | WO2022017338A1 (https=) |
Cited By (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116368140A (zh) * | 2020-09-10 | 2023-06-30 | 加舒布鲁姆生物公司 | 杂环glp-1激动剂 |
| CN117447493A (zh) * | 2023-12-25 | 2024-01-26 | 药康众拓(北京)医药科技有限公司 | 氘代吲哚嗪类化合物、药物组合物及其应用 |
| WO2025011664A1 (zh) | 2023-07-12 | 2025-01-16 | 歌礼制药(中国)有限公司 | Glp-1r激动剂的制剂及其制备方法 |
| WO2025026270A1 (zh) * | 2023-07-28 | 2025-02-06 | 上海翰森生物医药科技有限公司 | 一种苯并含氮杂环类衍生物调节剂、其制备方法和应用 |
| WO2025026436A1 (zh) * | 2023-08-02 | 2025-02-06 | 韦恩生物科技有限公司 | 一种含氮并环化合物及其制备方法和用途 |
| WO2025103443A1 (zh) * | 2023-11-16 | 2025-05-22 | 海思科医药集团股份有限公司 | 一种咪唑-2-酮衍生物及其在医药上的应用 |
| WO2025108361A1 (zh) * | 2023-11-21 | 2025-05-30 | 江苏恒瑞医药股份有限公司 | 杂环类化合物、其制备方法及其在医药上的应用 |
| WO2025119206A1 (en) * | 2023-12-05 | 2025-06-12 | Fortvita Biologics Inc. | Glp-1 receptor targeting compounds and uses thereof |
| WO2025124357A1 (zh) * | 2023-12-14 | 2025-06-19 | 广东众生睿创生物科技有限公司 | 一种杂环glp-1受体激动剂及其应用 |
| WO2025131043A1 (zh) * | 2023-12-22 | 2025-06-26 | 石药集团百克(山东)生物制药股份有限公司 | 一类多环化合物及其用途 |
| WO2025148997A1 (zh) * | 2024-01-10 | 2025-07-17 | 海思科医药集团股份有限公司 | 一种四氢吡啶并吡唑衍生物及其在医药上的应用 |
| WO2025176130A1 (zh) * | 2024-02-19 | 2025-08-28 | 上海壹迪生物技术有限公司 | 一种含吡唑并环类化合物、其药物组合物及其用途 |
| WO2025237355A1 (zh) * | 2024-05-17 | 2025-11-20 | 成都地奥九泓制药厂 | 一种glp-1受体激动剂化合物、其制备方法及其应用 |
| WO2025247390A1 (zh) * | 2024-05-31 | 2025-12-04 | 福佑泰生物制药公司 | 可用作glp-1r激动剂的杂双环化合物 |
| WO2026001866A1 (zh) * | 2024-06-24 | 2026-01-02 | 联邦生物科技(珠海横琴)有限公司 | 一种glp-1受体激动剂及其应用 |
| WO2026007995A1 (zh) * | 2024-07-03 | 2026-01-08 | 成都地奥九泓制药厂 | 一种杂环类glp-1受体激动剂化合物、其制备方法及其应用 |
| WO2026012416A1 (zh) * | 2024-07-11 | 2026-01-15 | 江苏德源药业股份有限公司 | 杂环类化合物、药物组合物及其应用 |
| WO2026031819A1 (en) * | 2024-08-06 | 2026-02-12 | Insilico Medicine Ip Limited | Novel compounds as glp-1r agonists and uses thereof |
| WO2026052129A1 (zh) * | 2024-09-09 | 2026-03-12 | 中国科学院上海药物研究所 | 多环杂芳烃类glp-1受体激动剂 |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JOP20190060A1 (ar) | 2016-09-26 | 2019-03-26 | Chugai Pharmaceutical Co Ltd | مشتق بيرازولو بيريدين له تأثير مساعد لمستقبل glp-1 |
| US12479854B2 (en) | 2021-07-29 | 2025-11-25 | Enanta Pharmaceuticals, Inc. | Spiropyrrolidine derived antiviral agents |
| WO2023016546A1 (en) * | 2021-08-12 | 2023-02-16 | Gasherbrum Bio, Inc. | Heterocyclic glp-1 agonists |
| PT4408840T (pt) | 2021-09-27 | 2025-10-07 | Terns Pharmaceuticals Inc | Ácidos benzimidazolocarboxílicos como agonistas de glp-1r |
| CN118401519A (zh) | 2021-10-25 | 2024-07-26 | 拓臻制药公司 | 作为glp-1r激动剂的化合物 |
| CN119095843A (zh) | 2022-02-23 | 2024-12-06 | 拓臻制药公司 | 作为glp-1r激动剂的化合物 |
| EP4522131A1 (en) * | 2022-05-11 | 2025-03-19 | Eli Lilly and Company | Glp1 tablet compositions |
| CN116003403B (zh) * | 2022-11-20 | 2024-07-23 | 药康众拓(北京)医药科技有限公司 | 一种氘代吲唑类化合物、药物组合物及其应用 |
| IL321043A (en) * | 2022-12-15 | 2025-07-01 | Sironax Ltd | SARM1 modulators, their preparations and uses |
| EP4652167A1 (en) * | 2023-01-17 | 2025-11-26 | Fochon Biosciences, Ltd. | Glp-1r agonists and uses thereof |
| CN120957993A (zh) | 2023-02-16 | 2025-11-14 | 加舒布鲁姆生物公司 | 杂环glp-1激动剂 |
| EP4568664B1 (en) | 2023-04-07 | 2026-04-01 | Terns Pharmaceuticals, Inc. | Combination comprising a thr-beta agonist and a glp-1r agonist for use in treating obesity |
| WO2025002250A1 (zh) * | 2023-06-29 | 2025-01-02 | 韦恩生物科技有限公司 | 一种glp-1受体激动剂及其制备方法和用途 |
| IL325536A (en) * | 2023-06-30 | 2026-02-01 | Chia Tai Tianqing Pharmaceutical Group Co Ltd | A compound containing a multi-fused ring structure |
| WO2025045208A1 (en) * | 2023-08-31 | 2025-03-06 | Gasherbrum Bio, Inc. | Heteroaryl-heterocycloalkyl-based glp-1 agonists |
| CN120981457A (zh) * | 2023-09-14 | 2025-11-18 | 歌礼制药(中国)有限公司 | Glp-1r激动剂及其治疗方法 |
| CN121941685A (zh) | 2023-11-10 | 2026-04-28 | 重庆药友制药有限责任公司 | 一种glp-1r激动剂化合物及其应用 |
| TW202521534A (zh) * | 2023-11-24 | 2025-06-01 | 香港商歌禮製藥(中國)有限公司 | Glp-1r 激動劑及其治療方法 |
| CN117777111A (zh) * | 2023-12-26 | 2024-03-29 | 上海苏博医药科技有限公司 | 一种Orforglipron关键中间体的合成方法及其中间体 |
| WO2025158275A1 (en) | 2024-01-24 | 2025-07-31 | Pfizer Inc. | Combination therapy using glucose-dependent insulinotropic polypeptide receptor antagonist compounds and glp-1 receptor agonist compounds |
| WO2025162065A1 (zh) * | 2024-01-30 | 2025-08-07 | 海创药业股份有限公司 | 一种具有glp-1受体激动剂作用的小分子化合物及其用途 |
| WO2025175249A1 (en) | 2024-02-14 | 2025-08-21 | Olema Pharmaceuticals, Inc. | Estrogen receptor modulators and uses thereof |
| TW202600132A (zh) | 2024-03-08 | 2026-01-01 | 美商安尼波那生物公司 | 用於治療肥胖症及提高減重之方法 |
| TW202602880A (zh) * | 2024-03-29 | 2026-01-16 | 美商拜歐美亞富成股份有限公司 | 雜環glp-1r促效劑 |
| WO2025209515A1 (zh) * | 2024-04-03 | 2025-10-09 | 广州市联瑞制药有限公司 | 一种glp-1受体激动剂及其制备方法和应用 |
| WO2025259825A1 (en) | 2024-06-12 | 2025-12-18 | Eli Lilly And Company | Glp-1 npa therapies for maintaining body weight loss or reduced hba1c levels following a prior glp-1 ra treatment |
| WO2025261454A1 (zh) * | 2024-06-19 | 2025-12-26 | 上海翰森生物医药科技有限公司 | 一种含氮大环化合物衍生物调节剂及其制备方法和应用 |
| WO2025264023A1 (en) * | 2024-06-19 | 2025-12-26 | Chong Kun Dang Pharmaceutical Corp. | Glp-1 receptor agonist, and uses thereof |
| WO2026012449A1 (zh) * | 2024-07-12 | 2026-01-15 | 联邦生物科技(珠海横琴)有限公司 | 一种具有glp-1受体激动剂效应的杂环化合物及其应用 |
| WO2026041075A1 (en) * | 2024-08-21 | 2026-02-26 | Gasherbrum Bio, Inc. | Gpl-1 agonists |
| CN119100966B (zh) * | 2024-09-02 | 2025-09-09 | 上海毕得医药科技股份有限公司 | 一种溴代吡咯甲酸甲酯的合成方法 |
| WO2026055512A1 (en) * | 2024-09-05 | 2026-03-12 | Biomea Fusion, Inc. | Combination of a menin inhibitor with a pyrazolopiperidine glp-1 receptor agonist for treating diabetes and obesity |
| CN120309500B (zh) * | 2025-06-19 | 2025-08-15 | 南昌大学 | 奥格列龙原料中间体及合成方法与奥格列龙原料合成方法 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109790161A (zh) * | 2016-09-26 | 2019-05-21 | 中外制药株式会社 | 具有glp-1受体激动剂作用的吡唑并吡啶衍生物 |
| WO2019166951A1 (en) * | 2018-02-28 | 2019-09-06 | Novartis Ag | Indole-2-carbonyl compounds and their use for the treatment of hepatitis b |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| JP6278472B2 (ja) | 2013-02-27 | 2018-02-14 | 塩野義製薬株式会社 | Ａｍｐｋ活性化作用を有するインドールおよびアザインドール誘導体 |
| JP7461104B2 (ja) | 2017-11-29 | 2024-04-03 | 中外製薬株式会社 | Ｇｌｐ－１受容体アゴニスト作用を持つピラゾロピリジン誘導体を含有する医薬組成物 |
-
2021
- 2021-07-20 US US17/380,084 patent/US12037339B2/en active Active
- 2021-07-20 AU AU2021311567A patent/AU2021311567B2/en active Active
- 2021-07-20 MX MX2023000943A patent/MX2023000943A/es unknown
- 2021-07-20 CA CA3186217A patent/CA3186217A1/en active Pending
- 2021-07-20 EP EP21749074.7A patent/EP4182020A1/en active Pending
- 2021-07-20 WO PCT/CN2021/107216 patent/WO2022017338A1/en not_active Ceased
- 2021-07-20 BR BR112023000932A patent/BR112023000932A2/pt unknown
- 2021-07-20 PH PH1/2023/550130A patent/PH12023550130A1/en unknown
- 2021-07-20 JP JP2023504008A patent/JP7569443B2/ja active Active
- 2021-07-20 IL IL299704A patent/IL299704A/en unknown
- 2021-07-20 KR KR1020237005845A patent/KR102936860B1/ko active Active
- 2021-07-20 KR KR1020267006827A patent/KR20260040657A/ko active Pending
- 2021-07-20 UA UAA202300616A patent/UA130727C2/uk unknown
- 2021-07-20 PE PE2023000103A patent/PE20230854A1/es unknown
- 2021-07-20 CN CN202180063652.8A patent/CN116390926A/zh active Pending
- 2021-11-02 US US17/516,932 patent/US11584751B1/en active Active
-
2023
- 2023-01-19 CL CL2023000196A patent/CL2023000196A1/es unknown
- 2023-02-09 CO CONC2023/0001407A patent/CO2023001407A2/es unknown
-
2024
- 2024-05-14 US US18/663,450 patent/US20250059192A1/en active Pending
- 2024-10-04 JP JP2024174734A patent/JP7795064B2/ja active Active
-
2025
- 2025-09-24 AU AU2025237942A patent/AU2025237942A1/en active Pending
- 2025-11-28 JP JP2025207454A patent/JP2026035735A/ja active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109790161A (zh) * | 2016-09-26 | 2019-05-21 | 中外制药株式会社 | 具有glp-1受体激动剂作用的吡唑并吡啶衍生物 |
| WO2019166951A1 (en) * | 2018-02-28 | 2019-09-06 | Novartis Ag | Indole-2-carbonyl compounds and their use for the treatment of hepatitis b |
Non-Patent Citations (1)
| Title |
|---|
| 尤启冬主编: "《药物化学》", 31 January 2004, 化学工业出版社, pages: 32 - 34 * |
Cited By (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116368140A (zh) * | 2020-09-10 | 2023-06-30 | 加舒布鲁姆生物公司 | 杂环glp-1激动剂 |
| WO2025011664A1 (zh) | 2023-07-12 | 2025-01-16 | 歌礼制药(中国)有限公司 | Glp-1r激动剂的制剂及其制备方法 |
| WO2025026270A1 (zh) * | 2023-07-28 | 2025-02-06 | 上海翰森生物医药科技有限公司 | 一种苯并含氮杂环类衍生物调节剂、其制备方法和应用 |
| WO2025026436A1 (zh) * | 2023-08-02 | 2025-02-06 | 韦恩生物科技有限公司 | 一种含氮并环化合物及其制备方法和用途 |
| WO2025103443A1 (zh) * | 2023-11-16 | 2025-05-22 | 海思科医药集团股份有限公司 | 一种咪唑-2-酮衍生物及其在医药上的应用 |
| WO2025108361A1 (zh) * | 2023-11-21 | 2025-05-30 | 江苏恒瑞医药股份有限公司 | 杂环类化合物、其制备方法及其在医药上的应用 |
| WO2025119206A1 (en) * | 2023-12-05 | 2025-06-12 | Fortvita Biologics Inc. | Glp-1 receptor targeting compounds and uses thereof |
| WO2025124357A1 (zh) * | 2023-12-14 | 2025-06-19 | 广东众生睿创生物科技有限公司 | 一种杂环glp-1受体激动剂及其应用 |
| WO2025131043A1 (zh) * | 2023-12-22 | 2025-06-26 | 石药集团百克(山东)生物制药股份有限公司 | 一类多环化合物及其用途 |
| CN117447493A (zh) * | 2023-12-25 | 2024-01-26 | 药康众拓(北京)医药科技有限公司 | 氘代吲哚嗪类化合物、药物组合物及其应用 |
| WO2025148997A1 (zh) * | 2024-01-10 | 2025-07-17 | 海思科医药集团股份有限公司 | 一种四氢吡啶并吡唑衍生物及其在医药上的应用 |
| WO2025176130A1 (zh) * | 2024-02-19 | 2025-08-28 | 上海壹迪生物技术有限公司 | 一种含吡唑并环类化合物、其药物组合物及其用途 |
| WO2025237355A1 (zh) * | 2024-05-17 | 2025-11-20 | 成都地奥九泓制药厂 | 一种glp-1受体激动剂化合物、其制备方法及其应用 |
| WO2025247390A1 (zh) * | 2024-05-31 | 2025-12-04 | 福佑泰生物制药公司 | 可用作glp-1r激动剂的杂双环化合物 |
| WO2026001866A1 (zh) * | 2024-06-24 | 2026-01-02 | 联邦生物科技(珠海横琴)有限公司 | 一种glp-1受体激动剂及其应用 |
| WO2026007995A1 (zh) * | 2024-07-03 | 2026-01-08 | 成都地奥九泓制药厂 | 一种杂环类glp-1受体激动剂化合物、其制备方法及其应用 |
| WO2026012416A1 (zh) * | 2024-07-11 | 2026-01-15 | 江苏德源药业股份有限公司 | 杂环类化合物、药物组合物及其应用 |
| WO2026031819A1 (en) * | 2024-08-06 | 2026-02-12 | Insilico Medicine Ip Limited | Novel compounds as glp-1r agonists and uses thereof |
| WO2026052129A1 (zh) * | 2024-09-09 | 2026-03-12 | 中国科学院上海药物研究所 | 多环杂芳烃类glp-1受体激动剂 |
Also Published As
| Publication number | Publication date |
|---|---|
| BR112023000932A2 (pt) | 2023-10-03 |
| PH12023550130A1 (en) | 2024-06-24 |
| AU2025237942A1 (en) | 2025-10-16 |
| IL299704A (en) | 2023-03-01 |
| WO2022017338A1 (en) | 2022-01-27 |
| JP7795064B2 (ja) | 2026-01-07 |
| AU2021311567A1 (en) | 2023-02-16 |
| JP2026035735A (ja) | 2026-03-04 |
| US20250059192A1 (en) | 2025-02-20 |
| PE20230854A1 (es) | 2023-05-29 |
| US11584751B1 (en) | 2023-02-21 |
| KR20230048056A (ko) | 2023-04-10 |
| MX2023000943A (es) | 2023-02-22 |
| EP4182020A1 (en) | 2023-05-24 |
| CL2023000196A1 (es) | 2023-09-15 |
| AU2021311567B2 (en) | 2025-07-10 |
| UA130727C2 (uk) | 2026-04-29 |
| CO2023001407A2 (es) | 2023-02-16 |
| JP2025004124A (ja) | 2025-01-14 |
| US12037339B2 (en) | 2024-07-16 |
| US20230051320A1 (en) | 2023-02-16 |
| JP7569443B2 (ja) | 2024-10-17 |
| KR20260040657A (ko) | 2026-03-25 |
| KR102936860B1 (ko) | 2026-03-12 |
| CA3186217A1 (en) | 2022-01-27 |
| JP2023534983A (ja) | 2023-08-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN116390926A (zh) | 四氢吡唑并-吡嗪基-二氢咪唑酮或四氢吡唑并-吡啶基-二氢咪唑酮化合物及其使用方法 | |
| CN117222631A (zh) | 苯基-[1,3]二氧杂环戊烯并[4,5-c]吡啶基-苯基-、苯基-[1,3]二氧杂环戊烯并[4,5-c]吡啶基-杂芳基-或苯基-[1,3]二氧杂环戊烯并[4,5-c]吡啶基-哌啶基-甲基-氧杂环丁烷基甲基-1h-苯并[d]咪唑-甲酸衍生物及其使用方法 | |
| US20240059710A1 (en) | KRAS G12D Inhibitors | |
| JP2023521698A (ja) | Ｋｒａｓの標的化分解のための化合物及び方法 | |
| WO2019114770A1 (zh) | Alk蛋白降解剂及其抗肿瘤应用 | |
| AU2024206693A1 (en) | Shp2 inhibitor and uses thereof | |
| KR20230142745A (ko) | Cdk2 억제제 및 그의 사용 방법 | |
| TWI783205B (zh) | 鹵代烯丙基胺類化合物及其用途 | |
| US20080096861A1 (en) | Chemical Compounds | |
| JP2023513373A (ja) | Ｐ２ｘ３修飾薬 | |
| WO2019241751A1 (en) | Ssao inhibitors and uses thereof | |
| JP2019511568A (ja) | 免疫調節剤としての三環式化合物 | |
| US20250326721A1 (en) | Ssao inhibitors and use thereof | |
| WO2022092141A1 (ja) | 抗ウイルス活性を有するアミド誘導体 | |
| CN113754635A (zh) | 稠环类化合物及其制备方法和用途 | |
| CA3016086A1 (en) | Compounds for the inhibition of cyclophilins and uses thereof | |
| CN117510504A (zh) | 蛋白激酶降解剂、药物及应用 | |
| KR20250038236A (ko) | 코로나바이러스 감염 치료용 화합물 | |
| BR122025022209A2 (pt) | Compostos de tetra-hidropirazolo-piridinil-di-hidroimidazolona, composição farmacêutica e seus usos | |
| EA049031B1 (ru) | Соединения тетрагидропиразоло-пиразинил-дигидроимидазолона или тетрагидропиразоло-пиридинил-дигидроимидазолона и способы их применения | |
| JP2026513938A (ja) | Ｉｒａｋ４ ｐｒｏｔａｃ | |
| US20260035361A1 (en) | Compounds for modulating hur (elavl1) | |
| CN117800895A (zh) | 草酸胺类衍生物、包含其的药物组合物及其医药用途 | |
| JP2025539873A (ja) | Ｈｕｒ（ｅｌａｖｌ１）を調節するための化合物 | |
| WO2024210198A1 (ja) | 新規なｂ０ａｔ１阻害剤 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20230908 Address after: Massachusetts Applicant after: Chengyi Biological (USA) Co. Address before: Room 402A, No. 326 Edison Road, Pudong New Area, Shanghai, 200120 Applicant before: Shanghai Chengyi Biotechnology Co.,Ltd. |
|
| TA01 | Transfer of patent application right | ||
| CB03 | Change of inventor or designer information |
Inventor after: Ren Zaifang Inventor after: Sun Xuefeng Inventor after: Zhou Jingye Inventor before: Ren Zaifang Inventor before: Sun Xuefeng Inventor before: Zhou Jingye Inventor before: Xu Qing |